Caries Prevention and Side Effects of Gum Arabic and Licorice Extracts Versus Chlorhexidine in High Caries Risk Patients

Sponsor
Cairo University (Other)
Overall Status
Completed
CT.gov ID
NCT03684993
Collaborator
(none)
63
1
3
1.2
53.3

Study Details

Study Description

Brief Summary

This trial is to test the caries prevention effect of Arabic gum and Licorice root extracts compared to Chlorhexidine in high caries risk patients. The antimicrobial efficacy and oral side effects from using these mouthwashes will also be tested.

Condition or Disease Intervention/Treatment Phase
Phase 2/Phase 3

Detailed Description

To evaluate the effect of Arabic gum (Acacia gum) and Licorice (Glycyrrhiza Glabra) mouthwashes in comparison to Chlorhexidine mouthwash on reducing caries incidence (development of new caries lesions), antimicrobial efficacy and the prevalence of oral side effects (adverse events) in high caries risk patients.

P: Population with high caries risk patients I1: Arabic Gum mouthwash I2: Licorice mouthwash

C: Chlorhexidine mouthwash O1: (Primary outcome) incidence of new caries lesions O2:

(secondary outcome) antimicrobial efficacy O3: oral side effects (adverse events) from mouthwash use

Study Design

Study Type:
Interventional
Actual Enrollment :
63 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Effect of Gum Arabic (Acacia Gum) and Licorice (Glycyrrhiza Glabra) Mouthwashes Compared to Chlorhexidine Mouthwash on Caries Prevention and the Prevalence of Oral Side Effects in High Caries Risk Patients: A Randomized Controlled Clinical Trial
Actual Study Start Date :
Dec 10, 2019
Actual Primary Completion Date :
Jan 15, 2020
Actual Study Completion Date :
Jan 15, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arabic gum extract

natural product Arabic gum (acacia gum) prepared as a mouthwash

Drug: Arabic, Gum
natural gum of acacia tree: Antimicrobial, anti-inflammatory medicinal plant used as a traditional oral hygiene substance (anticariogenic). It is used in treating sore throats, colds, bronchitis, toothache, gingival bleeding and mouth ulcers.
Other Names:
  • acacia gum
  • Experimental: Licorice root extract

    natural product Licorice (Glycyrrhiza Glabra) root extract prepared as a mouthwash

    Drug: Licorice Root
    natural licorice, herbal plant to relieve coughs, sore throats, and gastric inflammation. flavouring and sweetening agent. it's anti-caries, soothing anti-inflammatory and anticancer properties benefit against oral diseases and dental caries
    Other Names:
  • Glycyrrhiza Glabra
  • Active Comparator: Chlorhexidine

    chemical agent Chlorhexidine as a mouthwash

    Drug: Chlorhexidine
    chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
    Other Names:
  • Chlorhexidine gluconate or Chlorhexidine HCL
  • Outcome Measures

    Primary Outcome Measures

    1. Caries incidence - DMF index - visual and tactile clinical examination for caries detection according to the ICDAS critera [1 year (detected after 3, 6, 9 and 12 months)]

      development of new caries lesions. Clinical examination during study time to Measure DMF scoring index: any changes in number of decayed, missing and filled surfaces due to caries from baseline. Done according to International Caries Detection and Assessment System (ICDAS II criteria)

    Secondary Outcome Measures

    1. Antimicrobial efficacy - Incubating agar plates - Colony forming units (CFU/mL) [1 year (evaluated after 3, 6, 9 and 12 months)]

      Antimicrobial effect against streptococcus mutans and lactocbacilli: saliva samples collected and total bacterial count measured after agar plates incubating, expressed in colony forming units

    2. Side (Adverse) effect - subjective: Reporting Questionnaire - Binary outcome (yes/no) [1 year (recorded after each month of mouthwash use)]

      side effects from long term use of mouthwash

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 35 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • High caries risk patients according to CAMBRA caries risk assessment tool

    • Baseline of at least 2-3 active non-cavitated or cavitated carious lesionssz

    • Baseline salivary Mutans streptococci count ≥ 106 CFU/ml

    • Baseline salivary Lactobacilli count ≥ 104 CFU/ml

    • Baseline DMF index of at least 3-5

    • Cooperative patients approving to participate in the study

    Exclusion Criteria:
    • Any systemic conditions, severe medical complications

    • Significant past or current medical condition that may affect oral health or oral flora

    • Current medications (may affect the oral flora or salivary flow)

    • Allergy to any of the ingredients of the study products

    • Use of any antibiotics within the past 3 months

    • Use of any mouth rinses within the past 3 months

    • Current periodontitis (sites of probing pocket depth ≥ 5 mm)

    • Evidence of parafunctional habits

    • Dysfunction of temporomandibular joint

    • Presence of developmental dental anomalies

    • Presence of orthodontic appliance or removable prosthesis

    • Pregnancy

    • Xerostomia

    • Heavy smoking

    • Drug or alcohol addiction, or conditions that may decrease adhering to study protocol

    • Lack of compliance

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Faculty of Dentistry Cairo University Cairo Egypt 12411

    Sponsors and Collaborators

    • Cairo University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Dina Mohamed Kamal Eldin, Assistant lecturer, Cairo University
    ClinicalTrials.gov Identifier:
    NCT03684993
    Other Study ID Numbers:
    • arabic gum licorice CHX
    First Posted:
    Sep 26, 2018
    Last Update Posted:
    Feb 28, 2020
    Last Verified:
    Feb 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 28, 2020